Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost.
Ayrton BangoloSamir OzaRonit SlotkyAimee ChappellDavid SiegelHarsh ParmarNoa BiranDavid H VesolePooja PhullPublished in: Current stem cell research & therapy (2024)
This data allow clinicians to appropriately implement and inform patients of the therapeutic uses and clinical outcomes of stem cell boost in patients with multiply relapsed/refractory MM.
Keyphrases
- multiple myeloma
- stem cells
- acute lymphoblastic leukemia
- end stage renal disease
- acute myeloid leukemia
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- hodgkin lymphoma
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- palliative care
- electronic health record
- type diabetes
- cell therapy
- patient reported outcomes
- smoking cessation
- data analysis